Clinical and Experimental Medicine

Sodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

By Yufan Zhang, Jia-Jie Xie, Qi Wu, Yong Xu

Fig. 1. PRISMA flow diagram — Fig. 1. PRISMA flow diagramPRISMA flow diagramZhang et al.

Meta-analysis of randomised trialsInterventions

Preregistered CRD42024619019, declared no competing interests

The paper

Yufan Zhang, Jia-Jie Xie, Qi Wu, Yong Xu

Southwest Medical University

Clinical and Experimental Medicine, 3 Sep 2026

doi.org/10.1007/s10238-026-02300-6 PubMed 42690254

Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Gut7 Oct 2026
Model estimates pancreatic cancer risk in type 2 diabetes
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes